Table 1.
Risk factors for viridans group streptococci (VGS) bacteremia per group.
| Risk factors | Anginosus (n = 14) | Mitis (n = 20) | Sanguinis (n = 7) | Total (n = 43) |
|---|---|---|---|---|
| Pyrimidine antagonistsa | 5 (35.7%) | 13 (65%) | 4 (57%) | 22 (51.2%) |
| Neutropenia < 500 cell/mm3 | 1 (7.1%) | 11 (55%) | 5 (71.4%) | 19b (44.2%) |
| Steroids | 3 (21.4%) | 8 (40%) | 4 (57.1%) | 15 (34.9%) |
| Monoclonal antibody treatment | 3 (21.4%) | 5 (25%) | 1 (14.3%) | 9 (20.1%) |
| Radiotherapy in the previous 6 months | 2 (14.3%) | 4 (20%) | 1 (14.3%) | 7 (16.3%) |
| Aminoglycosides/metronidazole in previous 3 months | 4 (28.6%) | 1 (5%) | 1 (14.3%) | 6 (14.0%) |
| TMP/SMX in the past 3 months | 0 (0%) | 3 (15%) | 2 (28.6%) | 5 (11.6%) |
| Fluoroquinolones in the past 3 months | 3 (21.4%) | 0 (0%) | 1 (14.3%) | 4 (9.3%) |
| Head and neck radiotherapy | 0 (0%) | 2 (10%) | 1 (14.3%) | 3 (7%) |
a
Pyrimidine antagonist chemotherapy includes cytarabine (n = 15), gemcitabine (n = 2), capecitabine (n = 2), and 5-fluorouracil (n = 3).
b
S. salivarius is not shown in the table, but is included in this percentage, since the only risk factor found was neutropenia in both cases.